Search Results
Search for other papers by Yansu Wang in
Google Scholar
PubMed
Search for other papers by Yun Shen in
Google Scholar
PubMed
Search for other papers by Tingting Hu in
Google Scholar
PubMed
Search for other papers by Yufei Wang in
Google Scholar
PubMed
Search for other papers by Xiaojing Ma in
Google Scholar
PubMed
Search for other papers by Haoyong Yu in
Google Scholar
PubMed
Search for other papers by Yuqian Bao in
Google Scholar
PubMed
Introduction Non-alcoholic fatty liver disease (NAFLD) is a metabolic stress-induced liver injury that is pathologically manifested by excessive triglyceride deposition in hepatocytes. It is the most prevalent chronic liver disease worldwide
Search for other papers by Jun-Xin Yan in
Google Scholar
PubMed
Search for other papers by Bin-Jing Pan in
Google Scholar
PubMed
Search for other papers by Ping-Ping Zhao in
Google Scholar
PubMed
Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, Gansu, China
Search for other papers by Li-Ting Wang in
Google Scholar
PubMed
Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, Gansu, China
Search for other papers by Jing-Fang Liu in
Google Scholar
PubMed
Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, Gansu, China
Search for other papers by Song-Bo Fu in
Google Scholar
PubMed
Introduction Non-alcoholic fatty liver disease (NAFLD), which is the excessive deposition of fat (>5% of the liver weight) in liver cells without causes such as heavy drinking, hypothyroidism, or drugs, is considered a liver manifestation of
Zealand Pharma A/S, Søborg, Denmark
Search for other papers by Iben Rix in
Google Scholar
PubMed
Search for other papers by Marie L Johansen in
Google Scholar
PubMed
Search for other papers by Asger Lund in
Google Scholar
PubMed
Search for other papers by Malte P Suppli in
Google Scholar
PubMed
Search for other papers by Elizaveta Chabanova in
Google Scholar
PubMed
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Gerrit van Hall in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Jens J Holst in
Google Scholar
PubMed
Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Nicolai J Wewer Albrechtsen in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Caroline Kistorp in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Steno Diabetes Center Copenhagen, Herlev, Denmark
Search for other papers by Filip K Knop in
Google Scholar
PubMed
restoring amino acid turnover. The price for this is, however, that glucose production increases, as glucagon action on glucose production seems to be preserved in non-alcoholic fatty liver disease (NAFLD) ( 10 , 12 ). The mechanisms underlying this hepatic
Search for other papers by Zhiyan Yu in
Google Scholar
PubMed
Search for other papers by Yueyue Wu in
Google Scholar
PubMed
Search for other papers by Rui Zhang in
Google Scholar
PubMed
Search for other papers by Yue Li in
Google Scholar
PubMed
Search for other papers by Shufei Zang in
Google Scholar
PubMed
Search for other papers by Jun Liu in
Google Scholar
PubMed
factor-1 and hypoalbuminemia. Non-alcoholic fatty liver disease (NAFLD) affecting multiple extrahepatic organs is considered a multi-system disease ( 2 ). Recent studies have shown that NAFLD is a high risk factor for osteoporosis ( 3 ). Several studies
Centre for Biological Timing, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
Search for other papers by Robert Maidstone in
Google Scholar
PubMed
Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, Manchester, UK
Search for other papers by Martin K Rutter in
Google Scholar
PubMed
Oxford Liver Unit, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, UK
Search for other papers by Thomas Marjot in
Google Scholar
PubMed
NIHR Oxford Health Biomedical Research Centre, and NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK
Search for other papers by David W Ray in
Google Scholar
PubMed
NIHR Oxford Health Biomedical Research Centre, and NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK
Search for other papers by Matthew Baxter in
Google Scholar
PubMed
for the Study of the Liver (EASL) , European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO) . EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease
Search for other papers by David Koeckerling in
Google Scholar
PubMed
Search for other papers by Jeremy W Tomlinson in
Google Scholar
PubMed
Search for other papers by Jeremy F Cobbold in
Google Scholar
PubMed
Why fight liver fat? What is NAFLD? Non-alcoholic fatty liver disease (NAFLD) is recognised as the most common aetiology of chronic liver disease, with an estimated global prevalence of 25.2%, and as a major cause of cirrhosis and
Search for other papers by Stephen J Winters in
Google Scholar
PubMed
Search for other papers by Charles R Scoggins in
Google Scholar
PubMed
Search for other papers by Duke Appiah in
Google Scholar
PubMed
Search for other papers by Dushan T Ghooray in
Google Scholar
PubMed
J Elisaf MS Germanidis G Giouleme O et al . The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An
Search for other papers by Panagiotis Anagnostis in
Google Scholar
PubMed
Search for other papers by Irene Lambrinoudaki in
Google Scholar
PubMed
Search for other papers by John C Stevenson in
Google Scholar
PubMed
Search for other papers by Dimitrios G Goulis in
Google Scholar
PubMed
, atherogenic dyslipidemia, glucose intolerance, arterial hypertension (AH) and non-alcoholic fatty liver disease (NAFLD), compared with premenopausal status ( 5 ). In detail, transition to menopause leads to body fat redistribution toward the male pattern of
Search for other papers by Till Ittermann in
Google Scholar
PubMed
Department of Zoology, Islamia College Peshawar (CU), Peshawar, Pakistan
Search for other papers by Rehman Mehmood Khattak in
Google Scholar
PubMed
Search for other papers by Marcello R P Markus in
Google Scholar
PubMed
Search for other papers by Jens-Peter Kühn in
Google Scholar
PubMed
Search for other papers by Marie-Luise Kromrey in
Google Scholar
PubMed
Search for other papers by Giovanni Targher in
Google Scholar
PubMed
Search for other papers by Antje Steveling in
Google Scholar
PubMed
DZHK (German Centre for Cardiovascular Research), Partner Site Greifswald, University Medicine, Greifswald, Germany
Search for other papers by Matthias Nauck in
Google Scholar
PubMed
Search for other papers by Henry Völzke in
Google Scholar
PubMed
Introduction Non-alcoholic fatty liver disease (NAFLD) is a common finding in individuals with obesity or type 2 diabetes mellitus and its prevalence is steeply increasing worldwide ( 1 ). Recent meta-analyses of observational studies revealed
Search for other papers by Nikolaj Rittig in
Google Scholar
PubMed
Search for other papers by Mads Svart in
Google Scholar
PubMed
Search for other papers by Niels Jessen in
Google Scholar
PubMed
Search for other papers by Niels Møller in
Google Scholar
PubMed
Search for other papers by Holger J Møller in
Google Scholar
PubMed
Search for other papers by Henning Grønbæk in
Google Scholar
PubMed
as obesity, sepsis, insulin resistance, diabetes mellitus type 2 (DM2) and non-alcoholic fatty liver disease (NAFLD) ( 1 , 2 , 3 , 4 , 5 , 6 ). These diseases are also associated with changes in the lipid metabolism, accelerated lipolysis and